Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ImmunoPrecise Antibodies Ltd.
< Previous
1
2
Next >
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 26, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
August 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
July 29, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
July 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
July 16, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
July 15, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
June 27, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
June 25, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
June 12, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
June 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
June 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
March 28, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
March 20, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
March 14, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
March 07, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
March 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
December 14, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
December 08, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
December 06, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Announces Proposed Public Offering of Common Shares
December 05, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
November 27, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
November 13, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
October 25, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Provides Update on Growth Strategy and Recent Share Price Movement
October 23, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Announces CFO Transition
September 19, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
September 14, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
September 08, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Announces Board Refreshment
September 05, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
IPA Responds to 13D Filing
August 09, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
July 14, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Tickers
IPA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.